Fate Therapeutics

Fate Therapeutics will present five studies on its iPSC-derived CAR T-cell therapy platform at the upcoming ASGCT Annual Meeting, highlighting potential applications across autoimmune diseases and cancer.

Design Therapeutics has appointed Chris Storgard, M.D., as Chief Medical Officer, bringing over two decades of leadership in drug development with experience advancing multiple assets through global regulatory approvals.

CRISPR-Cas9 gene editing is being used to enhance CAR-NK cell therapy by disrupting inhibitory genes like KLRC1, TGFBR2, CISH, and CD38 to improve cytotoxicity and metabolic fitness.

The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.

A Phase 1 clinical trial of FT596, an off-the-shelf CAR-NK cell therapy, demonstrates its safety in patients with various types of B-cell lymphoma.

Fate Therapeutics is expanding its focus to autoimmune diseases, leveraging its cell therapy platform with programs like FT819 and FT522.

• Fate Therapeutics presented initial Phase 1 data for FT825 / ONO-8250, a HER2-targeting CAR T-cell therapy, showing a favorable safety profile in advanced solid tumors. • Preclinical data highlights FT825's cancer-selective HER2 recognition, potentially reducing off-target toxicities compared to existing HER2-directed therapies. • The Phase 1 study observed CAR T-cell expansion and activation in patients' peripheral blood, indicating potential for effective tumor targeting. • FT825 incorporates novel synthetic controls designed to enhance safety and efficacy in treating solid tumors, addressing limitations of current CAR T-cell therapies.

• Fate Therapeutics' FT825/ONO-8250, a HER2-targeting CAR-T cell therapy, shows a favorable safety profile in an early-stage trial for advanced solid tumors. • Preclinical data highlights the therapy's cancer-selective HER2 targeting, reducing off-tumor toxicities compared to traditional HER2-directed treatments. • Initial results from the Phase 1 study indicate CAR T-cell expansion and activation in patients, suggesting potential for clinical efficacy. • The FT825 / ONO-8250 incorporates seven novel synthetic controls of CAR T-cell function designed to overcome multiple mechanisms.

Fate Therapeutics has treated the first patient with systemic lupus erythematosus using FT819, an off-the-shelf CD19-targeted CAR-T cell therapy derived from induced pluripotent stem cells.